The Life Sciences 2030 Index
The global response to the COVID-19 pandemic has demonstrated the potential for innovation and science to overcome major health challenges and support a stronger society.
There is a unique opportunity for the UK to become a global hub for life sciences investment over the next decade, helping the nation become healthier, wealthier and more resilient. Bristol Myers Squibb (BMS) commissioned PwC UK to develop the Life Sciences 2030 report to identify how best to achieve this goal.
Based on extensive research and insights from experts from across the sector, the report sets out the opportunities and challenges for the UK in the next decade, and the health and economic impacts from achieving the vision for the UK.
The Life Science 2030 Index provides a long-term view of the UK’s international competitiveness in the sector and progress towards delivering on the Government’s aspirations for a global life sciences hub. It combines multiple indicators to create a ranking of the relative performance of the UK in life sciences competitiveness against a number of comparator markets.
If you have any questions about our research, please do not hesitate to get in touch.
